AQR Capital Management’s Inozyme Pharma INZY Stock Holding History

AQR Capital Management’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-80,614	Closed	-$322K	–	3526
2025 Q2	$322K	Buy	80,614 +1,537	+2%	+$3.81K	﹤0.01%	2835
2025 Q1	$72K	Buy	+79,077	New	+$110K	﹤0.01%	3059
2024 Q3	–	Sell	-10,807	Closed	-$48.2K	–	2822
2024 Q2	$48.2K	Sell	10,807 -16,909	-61%	-$82K	﹤0.01%	2545
2024 Q1	$212K	Sell	27,716 -18,197	-40%	-$99.8K	﹤0.01%	2241
2023 Q4	$196K	Buy	45,913 +26,169	+133%	+$93K	﹤0.01%	2221
2023 Q3	$82.9K	Buy	+19,744	New	+$100K	﹤0.01%	2246

AQR Capital Management's INZY Position: Q3 2025 in Review

AQR Capital Management sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 80,614 shares — an estimated $322K sold.

AQR Capital Management first reported a position in INZY in Q3 2023 and held it in 6 quarters. The position peaked at $322K in Q2 2025. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

AQR Capital Management reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
AQR Capital Management sold 80,614 Inozyme Pharma shares in Q3 2025, an estimated $322K.
AQR Capital Management first reported a position in Inozyme Pharma in Q3 2023 and held it in 6 quarters.
AQR Capital Management's Inozyme Pharma position peaked at $322K in Q2 2025.
0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.